Coeptis Therapeutics, Inc. (COEP) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-5.20 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.10 vs est $-5.20 (beat +1.9%). 2025: actual $-2.81 vs est $-3.40 (beat +17.4%). Analyst accuracy: 89%.
COEP Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Coeptis Therapeutics, Inc. in the past 3 months
EPS Estimates — COEP
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.10
vs Est –$5.20
▲ 2.0% off
2025
Actual –$2.81
vs Est –$3.40
▲ 21.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — COEP
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2025
Actual $0.001B
vs Est $0.001B
▼ 0.0% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
